[Translation] An open-label, multicenter phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and immunogenicity of RGL-232 in patients with advanced malignant solid tumors harboring KRAS mutations.
评价RGL-232在携带KRAS突变的晚期恶性实体瘤患者中的安全性和耐受性,确定RGL-232单药的最大耐受剂量(MTD)和/或推荐扩展剂量(RDE)
[Translation] To evaluate the safety and tolerability of RGL-232 in patients with advanced malignant solid tumors harboring KRAS mutations, and to determine the maximum tolerated dose (MTD) and/or recommended extension dose (RDE) of RGL-232 monotherapy.